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Antibiotics, commonly amoxycillin, tetracycline, metronidazole and
clarithromycin, are presently used in combination with anti-ulcer agents
such as omeprazole, colloidal bismuth subcitrate, and sucralfate to treat
Helicobacter pylori infection in patients with peptic ulcer, and com-
pelling evidence has accumulated that eradication of the organism pre-
vents duodenal ulcer relapse. The latest combination (MACE I)
involved omeprazole, amoxycillin ormetronidazole, and clarithromycin
and claimed 90-96 percent success in H. pylori eradication. While the
eradication rates ofthe bacteria are usually between 60-80 percent, the
healing rates ofduodenal ulcer using these regimens have been remark-
ably high, often over 90 percent, even with regimens that do not contain
proton-pump inhibitors. Antibiotics alone, such as furazolidone and
metronidazole, have been reported to heal peptic ulcer with various suc-
cesses. In a recent double-blind placebo-controlled study, we showed
that antibiotics alone, in the form of metronidazole, amoxycillin and
clarithromycin, effectively healed 92.5 percent of patients with duode-
nal ulcer, and that the healing was largely accountable by clearance of
H. pylori. Thus, the presentday evidence indicates that both healing and
prevention ofrelapse ofpeptic ulcer can be achieved by treatment ofH.
pylori. Metronidazole resistance is emerging rapidly, especially in Asia,
and is likely to affect eradication success. At this point in time, the best
regimen for peptic ulcer associated with H. pylori includes the use of a
proton-pump inhibitor plus two antibiotics for one to two weeks.
INTRODUCTION
The observation that treatment of Helicobacterpylori infection of the stomach pre-
vents the relapse ofduodenal ulcer [1, 2, 3] and gastric ulcer [4] forms the first clue that
the organism has an etiological role in these conditions and the platform for the advocate
to eradicate the organism in patients with peptic ulcer. A regimen containing colloidal bis-
muth subcitrate, which is a gastroprotective ulcer-healing agent, and two antibiotics,
metronidazole and amoxycillin or tetracycline became the classical triple therapy [5], and
achieved an eradication rate (i.e., negative test for H. pylori at least four weeks after
antibacterial treatment) of about 80 percent in most reported series. Side effects were
common, and were mostly ascribed, and rightly so, to the antibiotics employed (Table 1).
There has been a massive proliferation ofH. pylori related therapeutic trials in recent
years, and close to 500 have been reported. A major problem with these trials has been a
distinct lack of a controlled design except in about two dozens of them.
OMEPRAZOLE-BASED ERADICATION REGIMENS
It was observed that omeprazole, a proton-pump inhibitor, reduced the density of H.
pylori and improved the antral gastritis assosociated with duodenal ulcer [6]. The signifi-
cant rise in gastric pH has been considered to be responsible for the antibacterial action,
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Table 1. Side effects ofclassical triple therapy (colloidal bismuth subcitrate, metronidazle,
amoxycillin/tetracycline).
Nausea 20 percent
Esophageal bum 15 percent
Foul taste 15 percent
Diarrhea 10 percent
Vomiting 7.5 percent
Rash 5 percent
Dizziness 2 percent
Pseudomembranous colitis 1 percent
and for the enhancement of the action of certain antibiotics. The initial enthusiasm was
focused on dual therapy, namely omeprazole plus one antibiotic, usually amoxycillin, The
reported eradication rates, however, varied from 0 percent to 90 percent [7]. It would
appear from a recent meta-analysis [8] that with dual therapy using amoxycillin, a higher
eradication rate was achieved using omeprazole 20 mg twice daily (83 percent) than when
it was used in a single daily dose of40 mg (58 percent). Combination with clarithromycin
appeared promising [9, 10], with an eradication rate ofaround 80percent, but whether this
new enthusiasm will be sustained requires further controlled studies.
Dual therapy has largely been superceded by triple therapy because the latest triple
regimens have consistently achieved over 90 percent eradication rates [11, 12, 13, 14]. It
would also appear that omeprazole-based triple therapy for one week was as good as the
same therapy for two weeks [12, 13, 14] (Table 2). The latest trial involving 787 patients
was reported in Germany and showed that omeprazole, metronidazole and clarithromycin
for one week was successful in 90-95 percent, and that omeprazole, amoxycillin and clar-
ithromycin for one week was successful in 84-96 percent [15 ].
SUCRALFATE-BASED ERADICATION REGIMENS
Improvement of duodenal-ulcer associated antral gastritis has also been observed
with sucralfate, which was able to reduce the density ofH. pylori [16] and interfere with
Table 2. One-week triple therapies with omeprazole.
Author Medications* n Eradication rates
Bazzoli [11] omeprazole 20 mg qd 59 93 percent (55/59)
tinidazole 500 mg bid
clarithromycin 250 mg bid
Labenz [12] omeprazole 20 mg qd 40 95 percent (38/40)
metronidazole 400 mg bid
clarithromycin 250 mg bid
Jaup [13] omeprazole 20 mg bid 112 93 percent (104/112)
tinidazole 500 mg bid
clarithromycin 250 mg bid
Moayyedi [14] omeprazole 20 mg bid 47 94 percent (44/47)
tinidazole 500 mg bid
clarithromycin 250 mg bid
* qd: daily; bid: twice daily
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the colonization of the organism to the gastric epithelium [17]. Dual therapy with sucral-
fate and amoxycillin achieved an eradication rate of40 percent [18], which was similar to
those observed in dual therapy using bismuth compounds. A total of six studies have
examined triple therapy using sucralfate (usually 4 g daily in divided doses) with two
other antibiotics, and the eradication rates achieved were about 80 percent, ranging from
59 percent to 100 percent [19, 20, 21, 22, 23, 24]. The healing rates of duodenal ulcer
reported in these studies are generally over 90 percent. In one comparative study, the four-
week healing rates as shown by endoscopy were not distinguishable from those of
omeprazole combined with two antibiotics [20]. The results showed that the 4-week heal-
ing rates ofthe two regimens were both over 90 percent and that the H. pylori eradication
rates were 87 percent and 86 percent respectively. The high 4-week healing rate with the
sucralfate combination is surprising, since the use ofsucralfate alone has not been shown
in the past to achieve a 4-week healing rate of over 90 percent. In fact, a recent review
showed that the mean healing rate ofduodenal ulcer with sucralfate was 79 percent [25].
While this apparent improvement in healing rate needs to be confirmed by controlled stud-
ies, it is of interest to note that another anti-ulcer agent, ranitidine, has been shown when
combined with colloidal bismuth, metronidazole and tetracycline to have superior duode-
nal ulcer healing rate to ranitidine alone [26]. These results seem to suggest that eradica-
tion of H. pylori lead to additional healing.
DO ANTIBIOTICS DESIGNED TO ERADICATE H. PYLORI HEAL ULCERS?
It should be noted that even before the H. pylori era, the use ofantibiotics including
metronidazole [27] and furazolidone [28] had been reported to have various successes in
the healing of peptic ulcer. A recent double-blind placebo-controlled study [29] on 97
patients with duodenal ulcer in Hong Kong attempted to answer this fundamental ques-
tion, and showed that two weeks ofmetronidazole, amoxycillin and clarithromycin healed
92.5 percent of the patients at four weeks versus 36.6 percent in those treated with place-
bo. These results constituted the strongest evidence to this date that H. pylori infection is
aetiologically related to duodenal ulceration.
While this explanation is most likely true, the results also suggest that antibiotics may
possess ulcer-healing properties per se. Indeed, intragastric instillation ofamoxycillin sus-
pension and solution, as well as injection of amoxycillin by the intraperitoneal route, sig-
nificantly protected gastric mucosal damage by absolute ethanol in rats in a dosedepen-
dent manner [30]. This protection was lost when the animals were pretreated with
indomethacin, suggesting that the cytoprotection by amoxycillin was through the release
of prostaglandins. Gastric mucosal blood flow as measured by laser doppler flowmetry
and acid secretion were unaffected by amoxycillin, so that these mechanisms were unlike-
ly to be responsible for the cytoprotection. Similarly metronidazole, given either per oral
or intraperitoneally, dose-dependently prevented 40 percent ethanol-induced gastric
mucosal damage in the rat [31]. The protection was due to a direct vascular and glandular
cytoprotective property, and was neither through prostaglandin synthesis nor the improve-
ment of gastric mucosal blood flow. Oral clarithromycin, on the other hand, did not pro-
tect ethanol-induced gastric mucosal damage in the rat, but it prevented indomethacin-
induced damage in the animal [32]. We conclude from these studies that certain antibiotics
possess cytoprotective properties.
CONCLUSIONS
The concept has emerged to treat peptic ulcer as an infection and to control its symp-
toms with acid-reducing agents such as antacids, H2-receptor antagonists, and proton
pump inhibitors. The best available regimen is now close to ideal, and is able to eradicate
H. pylori infection in one week with few reported side-effects. While at the present time
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proton-pump inhibitors assume conveniently the antibacterial and anti-symptom role,
other players such as ranitidine bismuth citrate will come into the scene.
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